Persistent tachypnea of infancy: Follow up at school age.
children's interstitial lung disease
lung function test
neuroendocrine cell hyperplasia of infancy
pulmonary function test
rare diseases
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
20
06
2020
accepted:
28
07
2020
pubmed:
8
8
2020
medline:
23
3
2021
entrez:
8
8
2020
Statut:
ppublish
Résumé
Persistent tachypnea of infancy (PTI) is a rare pediatric lung disease of unknown origin. The diagnosis can be made by clinical presentation and chest high resolution computed tomography after exclusion of other causes. Clinical courses beyond infancy have rarely been assessed. Patients included in the Kids Lung Register diagnosed with PTI as infants and now older than 5 years were identified. Initial presentation, extrapulmonary comorbidities, spirometry and clinical outcome were analyzed. Thirty-five children older than 5 years with PTI diagnosed as infants were analyzed. At the age of 5 years, 74% of the patients were reported as asymptomatic and did not develope new symptoms during the observational period at school-age (mean, 3.9 years; range, 0.3-6.3). At the age of about 10 years, none of the symptomatic children had abnormal oxygen saturation during sleep or exercise anymore. Lung function tests and breathing frequency were within normal values throughout the entire observational period. PTI is a pulmonary disease that can lead to respiratory insufficiency in infancy. As at school age most of the previously chronically affected children became asymptomatic and did not develop new symptoms. We conclude that the overall clinical course is favorable.
Sections du résumé
BACKGROUND
Persistent tachypnea of infancy (PTI) is a rare pediatric lung disease of unknown origin. The diagnosis can be made by clinical presentation and chest high resolution computed tomography after exclusion of other causes. Clinical courses beyond infancy have rarely been assessed.
METHODS
Patients included in the Kids Lung Register diagnosed with PTI as infants and now older than 5 years were identified. Initial presentation, extrapulmonary comorbidities, spirometry and clinical outcome were analyzed.
RESULTS
Thirty-five children older than 5 years with PTI diagnosed as infants were analyzed. At the age of 5 years, 74% of the patients were reported as asymptomatic and did not develope new symptoms during the observational period at school-age (mean, 3.9 years; range, 0.3-6.3). At the age of about 10 years, none of the symptomatic children had abnormal oxygen saturation during sleep or exercise anymore. Lung function tests and breathing frequency were within normal values throughout the entire observational period.
CONCLUSIONS
PTI is a pulmonary disease that can lead to respiratory insufficiency in infancy. As at school age most of the previously chronically affected children became asymptomatic and did not develop new symptoms. We conclude that the overall clinical course is favorable.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3119-3125Informations de copyright
© 2020 The Authors. Pediatric Pulmonology Published by Wiley Periodicals LLC.
Références
Kurland G, Deterding RR, Hagood JS, et al. An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med. 2013;188:376-394. https://doi.org/10.1164/rccm.201305-0923ST
Deutsch GH, Young LR, Deterding RR, et al. Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med. 2007;176:1120-1128. https://doi.org/10.1164/rccm.200703-393OC
Das S, Langston C, Fan LL. Interstitial lung disease in children. Curr Opin Pediatr. 2011;23:325-331. https://doi.org/10.1097/MOP.0b013e3283464a37
Griese M, Haug M, Brasch F, et al. Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany. Orphanet J Rare Dis. 2009;4:26. https://doi.org/10.1186/1750-1172-4-26
Kornum JB, Christensen S, Grijota M, et al. The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study. BMC Pulm Med. 2008;8:24. https://doi.org/10.1186/1471-2466-8-24
Griese M, Irnstetter A, Hengst M, et al. Categorizing diffuse parenchymal lung disease in children. Orphanet J Rare Dis. 2015;10:122. https://doi.org/10.1186/s13023-015-0339-1
Rauch D, Wetzke M, Reu S, et al. Persistent tachypnea of infancy. Usual and aberrant. Am J Respir Crit Care Med. 2016;193:438-447. https://doi.org/10.1164/rccm.201508-1655OC
Deterding RR, Fan LL, Morton R, Hay TC, Langston C. Persistent tachypnea of infancy (PTI)-a new entity. Pediatr Pulmonol Suppl. 2001;23:72-73.
Hull J, Chow CW, Robertson CF. Chronic idiopathic bronchiolitis of infancy. Arch Dis Child. 1997;77:512-515. https://doi.org/10.1136/adc.77.6.512
Deterding RR, Pye C, Fan LL, Langston C. Persistent tachypnea of infancy is associated with neuroendocrine cell hyperplasia. Pediatr Pulmonol. 2005;40:157-165. https://doi.org/10.1002/ppul.20243
Nevel RJ, Garnett ET, Schaudies DA, Young LR. Growth trajectories and oxygen use in neuroendocrine cell hyperplasia of infancy. Pediatr Pulmonol. 2018;53:656-663. https://doi.org/10.1002/ppul.23958
Dishop MK. Paediatric interstitial lung disease: classification and definitions. Paediatr Respir Rev. 2011;12:230-237. https://doi.org/10.1016/j.prrv.2011.01.002
Brody AS, Crotty EJ. Neuroendocrine cell hyperplasia of infancy (NEHI). Pediatr Radiol. 2006;36:1328. https://doi.org/10.1007/s00247-006-0302-3
Spielberg DR, Brody AS, Baker ML, Woods JC, Towe CT. Ground-glass burden as a biomarker in neuroendocrine cell hyperplasia of infancy. Pediatr Pulmonol. 2019;54:822-827. https://doi.org/10.1002/ppul.24301
Popler J, Gower WA, Mogayzel PJ Jr, et al. Familial neuroendocrine cell hyperplasia of infancy. Pediatr Pulmonol. 2010;45:749-755. https://doi.org/10.1002/ppul.21219
Lukkarinen H, Pelkonen A, Lohi J, et al. Neuroendocrine cell hyperplasia of infancy: a prospective follow-up of nine children. Arch Dis Child. 2013;98:141-144. https://doi.org/10.1136/archdischild-2012-302115
Bush A, Griese M, Seidl E, Kerem E, Reu S, Nicholson AG. Early onset children's interstitial lung diseases: discrete entities or manifestations of pulmonary dysmaturity? Paediatr Respir Rev. 2019;30:65-71. https://doi.org/10.1016/j.prrv.2018.09.004
Gomes VC, Silva MC, Maia Filho JH, et al. Diagnostic criteria and follow-up in neuroendocrine cell hyperplasia of infancy: a case series. J Bras Pneumol. 2013;39:569-578. https://doi.org/10.1590/S1806-37132013000500007
Nevel RJ, Garnett ET, Worrell JA, et al. Persistent lung disease in adults with NKX2.1 mutation and familial neuroendocrine cell hyperplasia of infancy. Ann Am Thorac Soc. 2016;13:1299-1304. https://doi.org/10.1513/AnnalsATS.201603-155BC
O'Connor MG, Wurth M, Young LR. Rare becomes more common: recognizing neuroendocrine cell hyperplasia of infancy in everyday pulmonary consultations. Ann Am Thorac Soc. 2015;12:1730-1732. https://doi.org/10.1513/AnnalsATS.201507-422LE
Griese M, Seidl E, Hengst M, et al. International management platform for children's interstitial lung disease (chILD-EU). Thorax. 2018;73:231-239. https://doi.org/10.1136/thoraxjnl-2017-210519
Fan LL, Kozinetz CA. Factors influencing survival in children with chronic interstitial lung disease. Am J Respir Crit Care Med. 1997;156:939-942. https://doi.org/10.1164/ajrccm.156.3.9703051
Fan LL, Langston C. Chronic interstitial lung disease in children. Pediatr Pulmonol. 1993;16:184-196. https://doi.org/10.1002/ppul.1950160309
Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324-1343. https://doi.org/10.1183/09031936.00080312
Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet. 2011;377:1011-1018. https://doi.org/10.1016/S0140-6736(10)62226-X
Brody AS, Guillerman RP, Hay TC, et al. Neuroendocrine cell hyperplasia of infancy: diagnosis with high-resolution CT. AJR Am J Roentgenol. 2010;194:238-244. https://doi.org/10.2214/AJR.09.2743
Kerby GS, Wagner BD, Popler J, et al. Abnormal infant pulmonary function in young children with neuroendocrine cell hyperplasia of infancy. Pediatr Pulmonol. 2013;48:1008-1015. https://doi.org/10.1002/ppul.22718
Young LR, Brody AS, Inge TH, et al. Neuroendocrine cell distribution and frequency distinguish neuroendocrine cell hyperplasia of infancy from other pulmonary disorders. Chest. 2011;139:1060-1071. https://doi.org/10.1378/chest.10-1304
Cutz E, Yeger H, Pan J. Pulmonary neuroendocrine cell system in pediatric lung disease-recent advances. Pediatr Dev Pathol. 2007;10:419-435. https://doi.org/10.2350/07-04-0267.1